Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana was approved by the U.S. Food and Drug Administration (FDA), but it has not been available.
Jevtana which is used in combination with prednisone was approved by the FDA based on results from the Phase 3 TROPIC clinical study which involved 755 patients with mHRPC previously treated with a docetaxel-containing treatment regimen. Results from this trial demonstrated:
* a statistically significant 30%